Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule
Abstract
Introduction: Multiple Myeloma (MM) is a hematologic cancer caused by malignant plasma cells. Daratumumab is an immunoglobin G1 kappa human monoclonal antibody that targets CD38 antigen which is a cell surface glycoprotein highly expressed on myeloma cells. Daratumumab is FDA approved as monotherapy and in combination with dexamethasone and lenalidomide, bortezomib or pomalidomide in relapsed/refractory MM. Daratumumab is typically dosed:...
Paper Details
Title
Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule
Published Date
Nov 29, 2018
Journal
Volume
132
Issue
Supplement 1
Pages
2024 - 2024
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History